Skip to main content
. 2017 Jun 5;12(6):e0178168. doi: 10.1371/journal.pone.0178168

Fig 2. The effects of YM155 on RCC cells.

Fig 2

(A) Dose-response curves of YM155 on a panel of RCC cell lines with varying VHL status. Cells were incubated with YM155 for 72h. RCC786.0/EV, RCC786.0, NCC010, NCC035 and A498 are VHL null cell lines. RCC786.0/VHL.HA, ACHN and papillary RCC (P.RCC) are VHL positive cell lines. NCC010, NCC035 and P.RCC are patient derived RCC cell lines while the remaining RCC cell lines are commercially available. YM155 exhibited nanomolar growth inhibitory activity on these RCC cells but was significantly less potent on P.RCC. (B) Survivin levels in various RCC cell lines treated with increasing concentrations (20 nM– 80 nM) of YM155 for 48 h. YM155 effectively down-regulated survivin in a dose dependent manner, albeit to varying degrees depending on the cell type. (C) RCC786.0 and ACHN were treated with increasing concentrations (20 nM– 80 nM) of YM155 for 72h. YM155 effectively up-regulated cleaved PARP in a dose dependent manner.